Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

JPM Parting Shots: Immuno-Oncology Plans For Regeneron, Incyte, Molecular Partners

This article was originally published in Scrip

Executive Summary

Discussions with companies during last month's 34th Annual J.P. Morgan Healthcare Conference in San Francisco revealed that immuno-oncology remains as hot as ever with developers of targeted therapeutics shifting their focus to immunotherapies or agents that can be combined with the immune system-harnessing treatments for cancer.

You may also be interested in...



Allergan’s Ophthalmology Focus Grows Beyond Restasis And Glaucoma

Allergan is building a diverse ophthalmology portfolio with a pipeline of drugs, devices and procedures that could bolster the company’s eye care revenue beyond Restasis and glaucoma medicines.

Regeneron Emphasizes Pipeline Promise As Eylea Pricing Pressure Builds

Regeneron Pharmaceuticals Inc. executives emphasized the blockbuster potential of product candidates in the company's late-stage research and development pipeline on Aug. 4, while noting that the top-selling biologic Eylea (aflibercept) is facing increased reimbursement and competitive pressures.

Immuno-Oncology's Next Wave: Key Targets And Emerging Players

Doesn't every biopharma company have an immuno-oncology strategy these days? It certainly seems that way, considering the number of drug developers that are labeling their therapeutic candidates as immunotherapies regardless of whether the description truly fits their asset.

Topics

UsernamePublicRestriction

Register

SC064509

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel